Yiteng Jiahe (06998): The first subject has been dosed in the Phase Ib/II clinical trial of GB268.

Zhitong Finance APP reports that E-Teng Jiahe (06998) announced that the company's highly differentiated innovative PD-1/CTLA-4/VEGF tri-specific antibody GB268 for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer TNBC and hormone receptor-positive/HER2-negative HR+/HER2- breast cancer) has successfully completed the first dose administration to a subject in the Phase Ib/II clinical trial on August 5, 2026.